HONcode Certified

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

Bloggers

Carl Heneghan

Carl Heneghan

Deputy Director of the CEBM, GP and clinical lecturer at the University of Oxford.

Ami Banerjee

Ami Banerjee

Cardiology trainee and clinical research fellow at the University of Oxford

Carl Heneghan in action

CEBM Workshops Video Sample - Carl Heneghan - Diagnostic Tests

See Carl Heneghan in action in the CEBM's workshop videos.
Click here

Twitter TrustTheEvidence.net

Search the TRIP Database

TRIP Database


Recent comments

secondary prevention

25th August 2009 08:51am

Cardiac rehabilitation-the poor relation of treatment and prevention   Ami Banerjee

Coronary heart disease (CHD), which usually presents as a heart attack (or myocardial infarction, MI) is the most common cause of death and disability both in the UK and globally. The way in which CHD is treated and prevented therefore has huge implications for patients, health professionals and policymakers. Once a person has a heart attack, prevention of further heart attacks, stroke or death, or secondary prevention, is crucial. There is strong evidence for benefit of several drugs and treatments after heart attacks to this end, including aspirin, statins, ACE inhibitors and beta-blockers.

Read full article


3rd April 2009 12:00am

The promise of the PolyPill   Ami Banerjee

Cardiovascular disease (CVD) causes more mortality and morbidity than any other disease in both rich countries and poor countries [1]. The risk factors have been well-known for 50 years, but the optimal prevention strategy is still elusive.

Primary prevention treats individuals before they have a heart attack, whereas secondary prevention focuses on individuals who have had a heart attack. Several classes of drugs treat cardiovascular risk factors, demonstrating benefits in both primary and secondary prevention [2]. Many of these drugs are off-patent, and therefore cheap. Six years ago, Wald and Law hypothesised that a “Polypill”, containing three anti-hypertensives, folic acid, simvastatin and aspirin, could reduce the rates of CVD by over 80%, if all adults over the age of 55 years took it [3]. This week the Lancet published the first ever trial of such a Polypill [4, 5].

Read full article


Syndicate content